Literature DB >> 31933380

Systemic immune-inflammation index predicted overall survival and radiosensitivity in advanced non-small-cell lung cancer.

Xixi Li1, Pingping Hu2, Jing Liu3, Jiandong Zhang2, Qiqi Liu4.   

Abstract

Aim: To evaluate the predictive significance of systemic immune-inflammation index (SII) on overall survival (OS) and radiosensitivity in advanced non-small-cell lung cancer. Materials & methods: Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.
Results: The optimal cutoff for SII was 555.59, with an area under the curve of 0.782 (sensitivity: 76.6%, specificity: 71.9%, 95% CI: 0.730-0.833), respectively. Median OS (p < 0.001) in the low SII group (32.8 months) was better than the OS in the high SII group (8.5 months). SII-low group statistically exhibited a better radiosensitivity.
Conclusion: SII was an independent prognostic factor for OS and predictive factor for radiosensitivity. Higher level of SII associated with poorer OS and poorer radiosensitivity.

Entities:  

Keywords:  non-small-cell lung cancer; overall survival; radiosensitivity; systemic immune-inflammation index

Year:  2020        PMID: 31933380     DOI: 10.2217/fon-2019-0761

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  4 in total

1.  Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab.

Authors:  Wei-Xiang Qi; Yi Xiang; Shengguang Zhao; Jiayi Chen
Journal:  Cancer Immunol Immunother       Date:  2021-04-01       Impact factor: 6.968

2.  Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer.

Authors:  Fangqiu Fu; Chaoqiang Deng; Zhexu Wen; Zhendong Gao; Yue Zhao; Han Han; Shanbo Zheng; Shengping Wang; Yuan Li; Hong Hu; Yang Zhang; Haiquan Chen
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.

Authors:  Hui Yang; Kunlun Wang; Bingxu Li; Shenglei Li; Yan Li; Ling Yuan
Journal:  Front Oncol       Date:  2021-11-30       Impact factor: 6.244

Review 4.  The Relationship Between Systemic Immune Inflammatory Index and Prognosis of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review.

Authors:  Wei Huang; Jiayu Luo; Jianbo Wen; Mingjun Jiang
Journal:  Front Surg       Date:  2022-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.